Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169940 | 0.94 | SMN1; SMN2 (0.35) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL19426930 | 0.92 | SMN1; SMN2 (0.34) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL3177638 | 0.88 | SMN1; SMN2 (0.31) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL13798623 | 0.86 | SMN1; SMN2 (0.32) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL24227303 | 0.86 | SMN1; SMN2 (0.34) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL14449319 | 0.86 | — | — | |
| SCHEMBL23963458 | 0.86 | SMN1; SMN2 (0.31) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL26078255 | 0.83 | — | — | |
| SCHEMBL17151431 | 0.83 | SMN1; SMN2 (0.33) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL21441758 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901144-A1 | METHOD FOR STABILIZING PERFLUORO(2-METHYLENE-4-METHYL-1,3-DIOXOLANE)-CONTAINING COMPOSITION AND STABILIZED PERFLUORO(2-METHYLENE-4-METHYL-1,3-DIOXOLANE)-CONTAINING COMPOSITION | Tosoh Corporation (JP) | 2021-10-27 | — | — | EP | disclosed |
| US-20170373251-A1 | Substituted 1,2,3-Triylidenetris(cyanomethanylylidene) Cyclopropanes for VTE, Electronic Devices and Semiconducting Materials Using Them | NOVALED GMBH (DE) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170373251-A1 | Substituted 1,2,3-Triylidenetris(cyanomethanylylidene) Cyclopropanes for VTE, Electronic Devices and Semiconducting Materials Using Them | F2, F8, F3 | SMN1; SMN2 3290/4885TSHR 488/4885MEN1 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.